Sigilon Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). It is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. It also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.